OSCR
Oscar Health, Inc.
OSCR has the edge over SIBN overall, supported by stronger fundamentals and stronger modeled upside.
SIBN
SI-BONE, Inc.
SIBN has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SIBN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
SIBN's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SIBN PE Valuation
SIBN has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
SIBN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect SIBN's losses to shrink, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SIBN on earnings quality, reporting a profit while its opponent remains loss making.
SIBN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.31 | +$0.19 |
| Q2 2026 | -$0.34 | +$0.21 |
| Q1 2026 | -$0.39 | +$0.24 |
| Q4 2025 | -$0.44 | +$0.31 |
| Q3 2025 | -$0.50 | +$0.41 |
| Q2 2025 | -$0.55 | +$0.45 |
| Q1 2025 | -$0.63 | +$0.45 |
| Q4 2024 | -$0.75 | +$0.38 |
SIBN is still losing money, but far less than before: $0.31 per share over the past year, against $1.98 at its worst in mid-2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SIBN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SIBN on profitability, with a higher operating margin.
SIBN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $55.7M | +14% |
| Q2 2026 | $56M | +15% |
| Q1 2026 | $52.6M | +11% |
| Q4 2025 | $56.3M | +15% |
| Q3 2025 | $48.7M | +21% |
| Q2 2025 | $48.6M | +22% |
| Q1 2025 | $47.3M | +25% |
| Q4 2024 | $49M | +26% |
SIBN's revenue has grown year over year every quarter since late 2020: $56M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.8% | +3.3 points |
| Q2 2026 | -8.6% | +5.8 points |
| Q1 2026 | -9.7% | +6.1 points |
| Q4 2025 | -4.4% | +6.8 points |
| Q3 2025 | -11% | +7.9 points |
| Q2 2025 | -14% | +11 points |
| Q1 2025 | -16% | +16 points |
| Q4 2024 | -11% | +21 points |
SIBN's operating margin was −7.8% last quarter, up 3.3 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SIBN on cash generation, producing positive trailing cash flow while its opponent burns cash.
SIBN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$427K | +$193K |
| Q2 2026 | -$768K | +$1.2M |
| Q1 2026 | -$3.4M | +$3.5M |
| Q4 2025 | $440K | +$1.5M |
| Q3 2025 | -$620K | +$2.1M |
| Q2 2025 | -$1.9M | +$7.5M |
| Q1 2025 | -$7M | +$2.7M |
| Q4 2024 | -$1.1M | +$2.3M |
SIBN has burned cash in almost every quarter: −$4M over the past year, against −$11M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SIBN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +422K shares |
| 1 year | +4% | +1.7M shares |
| 3 years | +12% | +4.6M shares |
| 5 years | +35% | +11.6M shares |
| Available history | +82% | +20.2M shares |
SIBN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SIBN Net Leverage
SIBN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SIBN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 74.9 | Overbought |
| Stochastic | 76.7 | Neutral |
SIBN's weekly RSI is 75 (overbought) and its Stochastic is 77 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SIBN PE vs Healthcare Sector
SIBN has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
SIBN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.9 | 16% above |
| 20 week MA | $19.3 | 25% above |
| 50 week MA | $17.1 | 41% above |
| 100 week MA | $16.6 | 45% above |
| 200 week MA | $17.5 | 38% above |
SIBN has climbed back above all five of its weekly moving averages, and it's now 38% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SIBN on returns for 2026, with the stronger performance.
SIBN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.1 | $30.3 | +43% |
| 2021 | $30.3 | $21.9 | -28% |
| 2022 | $21.9 | $11.8 | -46% |
| 2023 | $11.8 | $21.0 | +78% |
| 2024 | $21.0 | $13.7 | -35% |
| 2025 | $13.7 | $20.4 | +48% |
| 2026 YTD | $20.4 | $24.1 | +19% |
SIBN has finished lower in three of the last six years. It's up 19% so far in 2026.